These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20197571)

  • 21. Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains.
    Yamamoto T; Kuroda M; Nishioka K
    Arch Dermatol Res; 2000 Nov; 292(11):535-41. PubMed ID: 11194891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of sensory neurogenic components in a bleomycin-induced scleroderma model using transient receptor potential vanilloid 1 receptor- and calcitonin gene-related peptide-knockout mice.
    Szabó A; Czirják L; Sándor Z; Helyes Z; László T; Elekes K; Czömpöly T; Starr A; Brain S; Szolcsányi J; Pintér E
    Arthritis Rheum; 2008 Jan; 58(1):292-301. PubMed ID: 18163477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis.
    Lange F; Bajtner E; Rintisch C; Nandakumar KS; Sack U; Holmdahl R
    Ann Rheum Dis; 2005 Apr; 64(4):599-605. PubMed ID: 15345503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Protective Effects of Bevacizumab in Bleomycin-Induced Experimental Scleroderma.
    Koca SS; Ozgen M; Dagli AF; Gozel N; Ozercan IH; Isik A
    Adv Clin Exp Med; 2016; 25(2):249-53. PubMed ID: 27627557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13.
    Aliprantis AO; Wang J; Fathman JW; Lemaire R; Dorfman DM; Lafyatis R; Glimcher LH
    Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2827-30. PubMed ID: 17307869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells.
    Ishikawa H; Takeda K; Okamoto A; Matsuo S; Isobe K
    J Invest Dermatol; 2009 Jul; 129(7):1688-95. PubMed ID: 19158840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mouse Models of Skin Fibrosis.
    Rius Rigau A; Luber M; Distler JHW
    Methods Mol Biol; 2021; 2299():371-383. PubMed ID: 34028755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bleomycin-induced scleroderma.
    Finch WR; Rodnan GP; Buckingham RB; Prince RK; Winkelstein A
    J Rheumatol; 1980; 7(5):651-9. PubMed ID: 6160247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New insights on chemically induced animal models of systemic sclerosis.
    Batteux F; Kavian N; Servettaz A
    Curr Opin Rheumatol; 2011 Nov; 23(6):511-8. PubMed ID: 21857225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet.
    Lakos G; Melichian D; Wu M; Varga J
    Pathobiology; 2006; 73(5):224-37. PubMed ID: 17314493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model.
    Liu S; Kapoor M; Denton CP; Abraham DJ; Leask A
    Arthritis Rheum; 2009 Sep; 60(9):2817-21. PubMed ID: 19714619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma.
    McCormick LL; Zhang Y; Tootell E; Gilliam AC
    J Immunol; 1999 Nov; 163(10):5693-9. PubMed ID: 10553100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical characterization of scleroderma-inducing glycosaminoglycan.
    Ishikawa H; Kitabatake M; Akiyama F
    Acta Derm Venereol; 1988; 68(5):378-84. PubMed ID: 2461019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease.
    Ruzek MC; Jha S; Ledbetter S; Richards SM; Garman RD
    Arthritis Rheum; 2004 Apr; 50(4):1319-31. PubMed ID: 15077316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma.
    Johnson SR; Feldman BM; Pope JE; Tomlinson GA
    J Rheumatol; 2009 Feb; 36(2):323-9. PubMed ID: 19040308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis.
    Akhmetshina A; Dees C; Busch N; Beer J; Sarter K; Zwerina J; Zimmer A; Distler O; Schett G; Distler JH
    Arthritis Rheum; 2009 Apr; 60(4):1129-36. PubMed ID: 19333940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mast cells in murine graft-versus-host disease: a model of immunologically induced fibrosis.
    Choi KL; Claman HN
    Immunol Ser; 1989; 46():641-51. PubMed ID: 2488873
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of DMARDs in systemic sclerosis therapy.
    Blank N; Max R; Lorenz HM
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii42-4. PubMed ID: 16987834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bleomycin-induced scleroderma.
    Sharma SK; Handa R; Sood R; Aggarwal P; Biswas A; Kumar U; Wali JP
    J Assoc Physicians India; 2004 Jan; 52():76-7. PubMed ID: 15633728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.